NCT06399536

Brief Summary

In this trial, we proposed an individualized acute normovolemic hemodilution (ANH), and conduct a randomized controlled trial to testify the effect of individualized ANH on red cells requirement for non-cardiac surgeries with anticipating major blood loss in adults.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
7mo left

Started Jun 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress75%
Jun 2024Dec 2026

First Submitted

Initial submission to the registry

April 29, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 3, 2024

Completed
29 days until next milestone

Study Start

First participant enrolled

June 1, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2026

Expected
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

December 4, 2024

Status Verified

December 1, 2024

Enrollment Period

2 years

First QC Date

April 29, 2024

Last Update Submit

December 1, 2024

Conditions

Keywords

acute normovolemic hemodilutionindividualized blood transfusionclinical trial

Outcome Measures

Primary Outcomes (1)

  • ABT requirement

    The perioperative allogeneic red blood cells consumption (Units per person).

    Up to 12 weeks.

Secondary Outcomes (5)

  • Proportion of transfused participants

    Up to 12 weeks.

  • Composite of in-hospital complications

    Up to 12 weeks.

  • Length of hospital stay

    Up to 12 weeks.

  • Postoperative hospital stay

    Up to 12 weeks.

  • Total in-hospital cost

    Up to 12 weeks.

Study Arms (2)

ANH group

EXPERIMENTAL

Participants will undergo individualized ANH based on the West China Liu's Score after anesthetic induction. The decision of autologous blood transfusion or allogeneic red cell transfusion will be made according to the West China Liu's Score.

Procedure: Individualized ANH

Control group

NO INTERVENTION

Participants will be treated as the routine clinical practice. The decision of blood transfusion will be guided as the transfusion guideline.

Interventions

Participants will undergo individualized ANH based on the West China Liu's Score after anesthetic induction. The decision of autologous blood transfusion or allogeneic red cell transfusion will be made according to the West China Liu's Score.

ANH group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing elective non-cardiac surgery with an anticipated red blood cells transfusion \>8 units (or 1600ml)
  • Aged 18\~75 years
  • Preoperative Hb level \> 120g/L for men and \> 110g/L for women.

You may not qualify if:

  • Refusal of blood transfusion
  • Cardiopulmonary insufficiency
  • Cerebrovascular disease
  • Renal impairment
  • Hemoglobinopathies or blood system diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China

RECRUITING

Related Publications (1)

  • Liao C, Tan J, An J, Zhong J, Lai X, Tian L, Liao R. Individualised acute normovolaemic haemodilution for non-cardiac surgery with anticipated high-dose red cell transfusion: study protocol for a randomised controlled trial in West China Hospital of Sichuan University. BMJ Open. 2025 Jan 2;15(1):e088326. doi: 10.1136/bmjopen-2024-088326.

Study Officials

  • Ren Liao

    West China Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The clinical investigators, the responsible anesthesiologists and surgeons, the research assistants, and the participants will not be blinded to the treatment assignment, and the statisticians responsible for outcome analysis will be blinded.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 29, 2024

First Posted

May 3, 2024

Study Start

June 1, 2024

Primary Completion (Estimated)

May 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

December 4, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will share

Individual participant data (IPD) with anonymity will be uploaded to the IPD sharing platform for data sharing. Data will be available after the agreement of the correspondence author upon reasonable request.

Shared Documents
STUDY PROTOCOL, CSR
Time Frame
5 years after the completion of the study.
Access Criteria
Upon request by email to PI.

Locations